Osteotech wins approval for Plexur M biocomposite in spine

Jul 30, 2008 (Datamonitor via COMTEX) -- OSTE | Quote | Chart | News | PowerRating -- Osteotech has announced that the FDA has cleared its 510(k) submission for Plexur M biocomposite for use in spinal applications.

In spinal applications, Plexur M may be used in conjunction with autograft as bone void filler. Previously, Osteotech has received the FDA clearance for Plexur M to be used in filling bony voids or gaps in the pelvis and extremities.

The Plexur technology is designed to utilize bone tissue for procedure-specific surgical applications in combination with a wide variety of polymers.

Sam Owusu-Akyaw, president and CEO of Osteotech, said: "We are very pleased to receive FDA clearance for use of Plexur M in the spine. Plexur M is the second, of what we hope to be many more, bone-polymer biocomposites developed under our proprietary Plexur(R) Technology."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index